StreetInsider.com News Articles

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fri, 16 Oct 2026 16:20:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Company’s newly-appointed Senior Vice President, Chief Information Officer, and seventeen other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fri, 16 Oct 2026 16:20:00 -0400

Stoke Therapeutics shares STK-002 data for eye disorder at AAO

Mon, 12 Oct 2026 08:00:57 -0400

Stoke Therapeutics, Inc. (Nasdaq: STOK) presented preclinical and early clinical data for its experimental treatment STK-002 at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans, according to a company press release.

STK-002 is an antisense oligonucleotide in development for autosomal dominant optic atrophy (ADOA), a rare inherited optic nerve disorder affecting approximately one in 25,000 people globally. ADOA causes progressive vision loss beginning in the first decade of life, and no approved treatments currently exist.

The condition is primarily caused by variants in the OPA1 gene, which result in reduced OPA1 protein expression. STK-002 is designed to increase functional

Stoke Therapeutics shares STK-002 data for eye disorder at AAO

Mon, 12 Oct 2026 08:00:57 -0400

The condition is primarily caused by variants in the OPA1 gene, which result in reduced OPA1 protein expression. STK-002 is designed to increase functional

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Mon, 12 Oct 2026 08:00:00 -0400

–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss–

–STK-002 represents a novel approach to ADOA by targeting the underlying disease biology, with the potential to be the first disease-modifying medicine for people living with ADOA–

–ADOA natural history findings and preclinical proof-of-concept data for STK-002 support the ongoing Phase 1 OSPREY study in people with ADOA–

–Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Mon, 12 Oct 2026 08:00:00 -0400

–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss–
–STK-002 represents a novel approach to ADOA by targeting the underlying disease biology, with the potential to be the first disease-modifying medicine for people living with ADOA–
–ADOA natural history findings and preclinical proof-of-concept data for STK-002 support the ongoing Phase 1 OSPREY study in people with ADOA–
–Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Ann

Tue, 06 Oct 2026 08:00:00 -0400

–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss–
–Preclinical data and progress of the Phase 1 OSPREY study of STK-002 in people with ADOA will be presented at AAO 2026–
–Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected to complete by year-end 2026; initial safety and efficacy data anticipated in H1 2027–

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Ann

Tue, 06 Oct 2026 08:00:00 -0400

–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss–
–Preclinical data and progress of the Phase 1 OSPREY study of STK-002 in people with ADOA will be presented at AAO 2026–
–Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected to complete by year-end 2026; initial safety and efficacy data anticipated in H1 2027–

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc.

Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA

Mon, 05 Oct 2026 07:00:40 -0400

Stoke Therapeutics (Nasdaq: STOK) announced it has completed a meeting with the U.S. Food and Drug Administration to align on key aspects of a planned New Drug Application for zorevunersen, an investigational treatment for Dravet syndrome.

Following the meeting, Stoke said it will use a multicomponent assessment of four prespecified Vineland-3 subdomains — expressive communication, receptive communication, interpersonal relationships and personal skills — to evaluate changes in cognition and behavior as a key secondary endpoint in its Phase 3 EMPEROR study. The analysis will use a multivariate mixed model for repeated measures.

The company plans to submit data to the FDA throughout

Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA

Mon, 05 Oct 2026 07:00:40 -0400

Stoke Therapeutics (Nasdaq: STOK) announced it has completed a meeting with the U.S. Food and Drug Administration to align on key aspects of a planned New Drug Application for zorevunersen, an investigational treatment for Dravet syndrome.

Following the meeting, Stoke said it will use a multicomponent assessment of four prespecified Vineland-3 subdomains — expressive communication, receptive communication, interpersonal relationships and personal skills — to evaluate changes in cognition and behavior as a key secondary endpoint in its Phase 3 EMPEROR study. The analysis will use a multivariate mixed model for repeated measures.

The company plans to submit data to the FDA throughout

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Mon, 05 Oct 2026 07:00:00 -0400

– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains –
– Phase 3 readout anticipated in the third quarter of 2027 to complete the planned U.S. NDA submission in the second half of 2027 –

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Mon, 05 Oct 2026 07:00:00 -0400

– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains –
– Phase 3 readout anticipated in the third quarter of 2027 to complete the planned U.S. NDA submission in the second half of 2027 –

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Mon, 05 Oct 2026 07:00:00 -0400

– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains –
– Phase 3 readout anticipated in the third quarter of 2027 to complete the planned U.S. NDA submission in the second half of 2027 –

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Mon, 05 Oct 2026 07:00:00 -0400

– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains –
– Phase 3 readout anticipated in the third quarter of 2027 to complete the planned U.S. NDA submission in the second half of 2027 –

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The

Form 4 Stoke Therapeutics, Inc. For: Oct 02 Filed by: Allan Jonathan

Fri, 02 Oct 2026 17:37:00 -0400
si-local-file:///var/storage/secattach/20261002/27143732.html

Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: Ticho Barry

Fri, 02 Oct 2026 17:36:00 -0400
si-local-file:///var/storage/secattach/20261002/27143724.html

Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan

Fri, 02 Oct 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20261002/27142575.html

Form SCHEDULE 13G Stoke Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Wed, 30 Sep 2026 18:31:00 -0400
si-local-file:///var/storage/secattach/20260930/27129801.html

Form 4 Stoke Therapeutics, Inc. For: Sep 23 Filed by: Cumbo Alexander

Fri, 25 Sep 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260925/27107509.html

Form 3 Stoke Therapeutics, Inc. For: Sep 23 Filed by: Cumbo Alexander

Fri, 25 Sep 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260925/27107467.html

Form 8-K Stoke Therapeutics, Inc. For: Sep 22

Fri, 25 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260925/27107392.html

Stoke Therapeutics adds Bo Cumbo to its board of directors

Wed, 23 Sep 2026 16:02:05 -0400

Stoke Therapeutics (Nasdaq: STOK) has appointed Bo Cumbo to its board of directors, the Bedford, Massachusetts-based biotechnology company announced. Concurrently, Edward Kaye, M.D., retired from his board role. Dr. Kaye had served on the board since 2017 and was the company's chief executive officer from 2017 to March 2025. He will continue to advise the board through the transition.

Mr. Cumbo has more than 30 years of experience in the biopharmaceutical industry, spanning commercial leadership, medicine launches, and corporate governance. Since 2022, he has served as president, chief executive officer, and director of Solid Biosciences. He previously served as the founding

Stoke Therapeutics adds Bo Cumbo to its board of directors

Wed, 23 Sep 2026 16:02:05 -0400

Stoke Therapeutics (Nasdaq: STOK) has appointed Bo Cumbo to its board of directors, the Bedford, Massachusetts-based biotechnology company announced. Concurrently, Edward Kaye, M.D., retired from his board role. Dr. Kaye had served on the board since 2017 and was the company's chief executive officer from 2017 to March 2025. He will continue to advise the board through the transition.

Mr. Cumbo has more than 30 years of experience in the biopharmaceutical industry, spanning commercial leadership, medicine launches, and corporate governance. Since 2022, he has served as president, chief executive officer, and director of Solid Biosciences. He previously served as the founding

Stoke Therapeutics adds Bo Cumbo to its board of directors

Wed, 23 Sep 2026 16:02:05 -0400

Stoke Therapeutics (Nasdaq: STOK) has appointed Bo Cumbo to its board of directors, the Bedford, Massachusetts-based biotechnology company announced. Concurrently, Edward Kaye, M.D., retired from his board role. Dr. Kaye had served on the board since 2017 and was the company's chief executive officer from 2017 to March 2025. He will continue to advise the board through the transition.

Mr. Cumbo has more than 30 years of experience in the biopharmaceutical industry, spanning commercial leadership, medicine launches, and corporate governance. Since 2022, he has served as president, chief executive officer, and director of Solid Biosciences. He previously served as the founding

Stoke Therapeutics adds Bo Cumbo to its board of directors

Wed, 23 Sep 2026 16:02:05 -0400

Stoke Therapeutics (Nasdaq: STOK) has appointed Bo Cumbo to its board of directors, the Bedford, Massachusetts-based biotechnology company announced. Concurrently, Edward Kaye, M.D., retired from his board role. Dr. Kaye had served on the board since 2017 and was the company's chief executive officer from 2017 to March 2025. He will continue to advise the board through the transition.

Mr. Cumbo has more than 30 years of experience in the biopharmaceutical industry, spanning commercial leadership, medicine launches, and corporate governance. Since 2022, he has served as president, chief executive officer, and director of Solid Biosciences. He previously served as the founding